AU2007313180A1 - Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto - Google Patents
Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto Download PDFInfo
- Publication number
- AU2007313180A1 AU2007313180A1 AU2007313180A AU2007313180A AU2007313180A1 AU 2007313180 A1 AU2007313180 A1 AU 2007313180A1 AU 2007313180 A AU2007313180 A AU 2007313180A AU 2007313180 A AU2007313180 A AU 2007313180A AU 2007313180 A1 AU2007313180 A1 AU 2007313180A1
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- methyl
- group
- biphenyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85261006P | 2006-10-17 | 2006-10-17 | |
US60/852,610 | 2006-10-17 | ||
US93435807P | 2007-06-11 | 2007-06-11 | |
US60/934,358 | 2007-06-11 | ||
PCT/US2007/022086 WO2008048609A1 (en) | 2006-10-17 | 2007-10-16 | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2007313180A1 true AU2007313180A1 (en) | 2008-04-24 |
Family
ID=39149258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007313180A Abandoned AU2007313180A1 (en) | 2006-10-17 | 2007-10-16 | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100240653A1 (es) |
EP (1) | EP2074086B1 (es) |
JP (1) | JP2010506918A (es) |
KR (1) | KR20090069333A (es) |
AR (1) | AR063226A1 (es) |
AT (1) | ATE512948T1 (es) |
AU (1) | AU2007313180A1 (es) |
CA (1) | CA2665204A1 (es) |
CL (1) | CL2007002977A1 (es) |
EA (1) | EA200970386A1 (es) |
IL (1) | IL197892A0 (es) |
MX (1) | MX2009004071A (es) |
PA (1) | PA8750901A1 (es) |
PE (1) | PE20081462A1 (es) |
TW (1) | TW200823204A (es) |
WO (1) | WO2008048609A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS20060035A (en) * | 2003-07-22 | 2008-08-07 | Arena Pharmaceuticals Inc., | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
JP2010529130A (ja) * | 2007-06-08 | 2010-08-26 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−1−{2−[4’−(3−メトキシ−プロパン−1−スルホニル)−ビフェニル−4−イル]−エチル}−2−メチル−ピロリジンの結晶形、およびその組成物ならびにそれに関連する方法 |
JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体 |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
JP2011518154A (ja) * | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−1−{2−[4’−(3−メトキシプロパン−1−スルホニル)−ビフェニル−4−イル]−エチル}−2−メチル−ピロリジンの合成に有用なプロセス |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
EP2364142B1 (en) | 2008-10-28 | 2018-01-17 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
GB201005511D0 (en) | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
DK3309150T3 (da) * | 2013-01-09 | 2021-08-30 | Arena Pharm Inc | (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物 |
WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
CN115160584B (zh) * | 2022-07-06 | 2024-03-22 | 西北工业大学 | 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
DE69319391T2 (de) * | 1992-09-14 | 1998-10-29 | Takeda Chemical Industries Ltd | 1,2,4-Oxadiazolyl oder 1,2,4-Thiadiazolyl-Derivate als Angiotensin II Antagonisten |
US5541217A (en) * | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
US20040044029A1 (en) * | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
ATE454372T1 (de) * | 2004-04-01 | 2010-01-15 | Lilly Co Eli | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen |
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
US7145005B2 (en) * | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
ATE429426T1 (de) * | 2004-09-07 | 2009-05-15 | Banyu Pharma Co Ltd | Carbamoylsubstituiertes spiro-derivat |
JP2008521847A (ja) * | 2004-12-03 | 2008-06-26 | エフ.ホフマン−ラ ロシュ アーゲー | H3拮抗剤としての3−置換ピリジン誘導体 |
CN101107227B (zh) * | 2005-01-19 | 2010-09-22 | 霍夫曼-拉罗奇有限公司 | 5-氨基吲哚衍生物 |
US20060188960A1 (en) * | 2005-02-18 | 2006-08-24 | Waters Stephen M | Chimeric histamine H3 receptor |
ATE409188T1 (de) * | 2005-06-17 | 2008-10-15 | Janssen Pharmaceutica Nv | Naphthyridinverbindungen |
JP5185120B2 (ja) * | 2005-09-16 | 2013-04-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh3受容体のモジュレーターとしてのシクロプロピルアミン |
EP1957479B1 (en) * | 2005-11-30 | 2011-03-02 | F. Hoffmann-La Roche AG | 1,5-substituted indol-2-yl amide derivatives |
PE20071136A1 (es) * | 2005-12-21 | 2007-12-29 | Schering Corp | Derivados de anilina sustituida como antagonistas de la histamina h3 |
JP2009530274A (ja) * | 2006-03-15 | 2009-08-27 | ワイス | ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物 |
PE20080371A1 (es) * | 2006-05-19 | 2008-04-09 | Wyeth Corp | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 |
AU2007256931B2 (en) * | 2006-05-30 | 2013-01-24 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
US7846930B2 (en) * | 2007-05-18 | 2010-12-07 | Janssen Pharmaceutica Nv | Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators |
CA2688110A1 (en) * | 2007-05-24 | 2008-12-04 | Wyeth Llc | Azacyclylbenzamide derivatives as histamine-3 antagonists |
TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
BRPI0817061A2 (pt) * | 2007-09-12 | 2015-03-24 | Wyeth Llc | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 |
EP2220045A1 (en) * | 2007-11-20 | 2010-08-25 | Janssen Pharmaceutica, N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
WO2009143153A1 (en) * | 2008-05-23 | 2009-11-26 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine h3 receptor |
US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
-
2007
- 2007-09-28 TW TW096136478A patent/TW200823204A/zh unknown
- 2007-10-10 AR ARP070104474A patent/AR063226A1/es not_active Application Discontinuation
- 2007-10-16 JP JP2009533349A patent/JP2010506918A/ja not_active Withdrawn
- 2007-10-16 EA EA200970386A patent/EA200970386A1/ru unknown
- 2007-10-16 KR KR1020097009992A patent/KR20090069333A/ko not_active Application Discontinuation
- 2007-10-16 PE PE2007001398A patent/PE20081462A1/es not_active Application Discontinuation
- 2007-10-16 AT AT07852791T patent/ATE512948T1/de not_active IP Right Cessation
- 2007-10-16 MX MX2009004071A patent/MX2009004071A/es active IP Right Grant
- 2007-10-16 AU AU2007313180A patent/AU2007313180A1/en not_active Abandoned
- 2007-10-16 WO PCT/US2007/022086 patent/WO2008048609A1/en active Application Filing
- 2007-10-16 CA CA002665204A patent/CA2665204A1/en not_active Abandoned
- 2007-10-16 EP EP07852791A patent/EP2074086B1/en active Active
- 2007-10-16 US US12/445,795 patent/US20100240653A1/en not_active Abandoned
- 2007-10-17 CL CL200702977A patent/CL2007002977A1/es unknown
- 2007-10-17 PA PA20078750901A patent/PA8750901A1/es unknown
-
2009
- 2009-04-05 IL IL197892A patent/IL197892A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20100240653A1 (en) | 2010-09-23 |
KR20090069333A (ko) | 2009-06-30 |
CA2665204A1 (en) | 2008-04-24 |
JP2010506918A (ja) | 2010-03-04 |
PE20081462A1 (es) | 2008-10-18 |
WO2008048609A1 (en) | 2008-04-24 |
MX2009004071A (es) | 2009-04-28 |
ATE512948T1 (de) | 2011-07-15 |
EP2074086B1 (en) | 2011-06-15 |
EA200970386A1 (ru) | 2009-10-30 |
AR063226A1 (es) | 2009-01-14 |
TW200823204A (en) | 2008-06-01 |
CL2007002977A1 (es) | 2008-06-06 |
PA8750901A1 (es) | 2009-03-31 |
IL197892A0 (en) | 2009-12-24 |
EP2074086A1 (en) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2074086B1 (en) | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto | |
EP2035372A1 (en) | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto | |
JP2005255685A (ja) | カンナビノイド受容体に作用する新規なピラゾール類似体 | |
AU2008319310A1 (en) | Biphenyl derivatives as modulators of the histamine-H3 receptor useful for the treatment of disorders related thereto | |
JP2008526887A (ja) | カンナビノイド受容体に作用する新規なヘテロピロール類似体 | |
AU2010257277A1 (en) | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | |
US20100331312A1 (en) | Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto | |
CA2650914A1 (en) | Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia | |
US20100292288A1 (en) | Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
CA2791431A1 (en) | Derivatives of aminoindanes, their preparation and their application in therapeutics | |
JP2006500314A (ja) | ヒスタミン−3受容体リガンドとしての1,3−ジ置換および1,3,3−トリ置換ピロリジン類ならびにそれらの治療用途 | |
Gluszok et al. | Design, solid-phase synthesis, and biological evaluation of novel 1, 5-diarylpyrrole-3-carboxamides as carbonic anhydrase IX inhibitors | |
WO2006051851A1 (ja) | 2,3,4,5-テトラヒドロ-1h-1,5-ベンゾジアゼピン誘導体、及び、医薬組成物 | |
CA2628527A1 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
EP2943473B1 (en) | Biphenyl-ethyl-pyrrolidine derivatives as histamine h3 receptor modulators for the treatment of cognitive disorders | |
WO2004108706A1 (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
CN103328446B (zh) | 用于治疗癌症的新的4-氨基-n-羟基-苯甲酰胺 | |
AU2006255642A1 (en) | 1-Hydroxycycloalkanecarboxamide derivatives as bradykinin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |